Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. ResMed, Inc.
  6. Financials
    RMD   US7611521078

RESMED, INC.

(RMD)
  Report
Delayed Nyse  -  04:00 2022-10-03 pm EDT
224.25 USD   +2.73%
09/19Insider Sell: Resmed
MT
09/14Transcript : ResMed Inc. Presents at BofA Securities Global Healthcare Conference 2022, Sep-14-2022 08:05 AM
CI
09/12Transcript : ResMed Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 08:45 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: June 2020 2021 2022 2023 2024 2025
Capitalization1 27 77635 90330 69132 838--
Enterprise Value (EV)1 28 48936 26331 19233 31832 53131 747
P/E ratio 45,0x76,1x39,6x36,3x31,6x26,9x
Yield 0,81%0,63%0,80%0,81%0,89%0,95%
Capitalization / Revenue 9,39x11,2x8,58x8,22x7,58x7,08x
EV / Revenue 9,63x11,3x8,72x8,34x7,51x6,84x
EV / EBITDA 29,5x33,8x26,8x25,2x22,0x20,0x
Price to Book 11,1x12,4x9,35x7,84x6,41x5,30x
Nbr of stocks (in thousands) 144 668145 640146 405146 433--
Reference price (USD) 192247210224224224
Announcement Date 08/05/202008/05/202108/11/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: June 2020 2021 2022 2023 2024 2025
Net sales1 2 9573 1973 5783 9964 3314 640
EBITDA1 9661 0741 1621 3231 4761 591
Operating profit (EBIT)1 8119041 0001 2311 3881 526
Operating Margin 27,4%28,3%28,0%30,8%32,1%32,9%
Pre-Tax Profit (EBT)1 7338849601 1291 2981 459
Net income1 6224757799071 0351 148
Net margin 21,0%14,8%21,8%22,7%23,9%24,8%
EPS2 4,273,245,306,187,108,33
Dividend per Share2 1,561,561,681,812,002,13
Announcement Date 08/05/202008/05/202108/11/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: June 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales1 895865915943973987
EBITDA1 290277295310325337
Operating profit (EBIT)1 249234255288293307
Operating Margin 27,8%27,1%27,9%30,5%30,1%31,1%
Pre-Tax Profit (EBT)1 237226238259272279
Net income1 202179195207218225
Net margin 22,5%20,7%21,3%22,0%22,4%22,7%
EPS2 1,371,221,331,371,451,49
Dividend per Share ------
Announcement Date 01/27/202204/28/202208/11/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: June 2020 2021 2022 2023 2024 2025
Net Debt1 713360502480--
Net Cash position1 ----3071 091
Leverage (Debt / EBITDA) 0,74x0,34x0,43x0,36x-0,21x-0,69x
Free Cash Flow1 7076342169731 0691 102
ROE (Net Profit / Equities) 27,2%29,0%27,2%25,8%25,1%23,6%
Shareholders' equity1 2 2851 6362 8613 5184 1284 864
ROA (Net Profit / Asset) 14,3%16,8%17,3%17,4%18,0%17,8%
Assets1 4 3482 8314 5005 2015 7606 458
Book Value Per Share2 17,319,922,428,635,042,3
Cash Flow per Share2 5,515,032,398,148,889,44
Capex1 95,3103135124130141
Capex / Sales 3,22%3,21%3,77%3,11%3,00%3,05%
Announcement Date 08/05/202008/05/202108/11/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
Explainer-What is the impact of Philips' recall of sleep apnea devices?
Key data
Capitalization (USD) 32 837 635 233
Net sales (USD) 3 578 127 000
Number of employees 8 160
Sales / Employee (USD) 438 496
Free-Float 77,1%
Free-Float capitalization (USD) 25 326 999 458
Avg. Exchange 20 sessions (USD) 103 341 834
Average Daily Capital Traded 0,31%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA